research Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease
A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.
Search
for
Sort by
Research
330-360 / 1000+ results 
research Electron beam tomography quantitation of coronary calcium and assessment for ischemic coronary disease: a complement to stress testing
Electron Beam Tomography (EBT) is a useful additional test to stress testing for detecting heart disease.
research Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
These new skin treatments are safer and more effective with minimal side effects.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice
Etoposide makes radiation therapy more effective against tumors without major side effects.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Worldwide Clinical and Real-World Exposure to Baricitinib
Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
research Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
research Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research Inherited epidermolysis bullosa: clinical and therapeutic aspects
The document concludes that inherited epidermolysis bullosa is a challenging genetic condition requiring multidisciplinary care and new treatments.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
Baricitinib shows promise in treating severe hair loss.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)
Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
research Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
Upadacitinib effectively treated severe hair loss in a child.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Efficacy and safety of ozenoxacin 1% cream, a novel antibiotic for the topical treatment of impetigo in children and adults
Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.
research Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.
research COMPARATIVE EVALUATION OF EFFICACY AND SAFETY OF TOPICAL METHOTREXATE WITH TRETINOIN VERSUS BETAMETHASONE WITH TRETINOIN IN PATIENTS OF ALOPECIA AREATA: A PROSPECTIVE RANDOMIZED DOUBLE-BLIND STUDY
Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
research Inhibition of 5α-Reductase, IL-6 Secretion, and Oxidation Process of Equisetum debile Roxb. ex Vaucher Extract as Functional Food and Nutraceuticals Ingredients
Equisetum debile extract, especially the ethyl acetate type, may be a promising natural ingredient for anti-hair loss products.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research “Prick or treat”: a case of systemic reaction during intradermal tests with beta-lactams
Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Targeted therapy in melanoma
New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
research Bempikibart shows its potential for hair regrowth in alopecia areata
Bempikibart may help regrow hair in people with alopecia areata.
research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.